The role of T cells and PD-L1 in advanced non-small cell lung carcinoma
10.3969/j.issn.1673-9701.2025.16.006
- VernacularTitle:T细胞与PD-L1在晚期非小细胞肺癌中的作用
- Author:
Nan ZHANG
1
;
Qingxin WANG
;
Qin ZHANG
Author Information
1. 中国人民武装警察部队海警总队医院肿瘤科,浙江嘉兴 314000
- Publication Type:Journal Article
- Keywords:
Regulatory T cell;
Programmed death-ligand 1;
Non-small cell lung carcinoma
- From:
China Modern Doctor
2025;63(16):22-25
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the role of regulatory T cells and exosome programmed death-ligand 1(PD-L1)in the immunotherapy of advanced non-small cell lung carcinoma(NSCLC).Methods Sixty patients with advanced NSCLC who visited China Coast Guard Hospital of the People's Armed Police Force from March 2022 to June 2024 were selected and included in lung carcinoma group.Among them,there were 30 patients squamous cell carcinoma and 30 patients with non-squamous cell carcinoma.Sixty healthy individuals undergoing physical examinations during the same period were selected as control group.Patients in squamous cell carcinoma group were treated with sintilimab+paclitaxel+cisplatin,while patients in non-squamous cell carcinoma group were treated with sintilimab+pemetrexed+carboplatin.Therapeutic effects and blood index results of two groups of patients were evaluated.Results The red blood cell count,hemoglobin,white blood cell count,platelets,CD3+,CD4+,CD4/CD8 and PD-L1 of patients in lung carcinoma group were significantly lower than those in control group(P＜0.05).The remission rate of patients in squamous cell carcinoma group was significantly higher than that in non-squamous cell carcinoma group(P＜0.05).After treatment,white blood cell count,CD8+,and exosome PD-L1 of patients in squamous cell carcinoma group were significantly lower than those in non-squamous cell carcinoma group,while red blood cell count,hemoglobin,platelets,CD3+,CD4+,and CD4/CD8 were significantly higher than those in non-squamous cell carcinoma group(P＜0.05).Conclusion There are differences in immune responses among different subtypes of lung carcinoma,and targeted treatment plans should be formulated based on pathological types.
